Ṣẹ̀yẹ Abímbọ́lá, Sumegha Asthana, Cristián Montenegro, Renzo Guinto et al.
The Coronavirus Disease 2019 (COVID-19AU : PleasenotethatCOVID 19hasbeendefinedasCoro ) pandemic, the Black Lives Matter and Women in Global Health movements, and ongoing calls to decolonise global health have all created space for uncomfortable but important conversations that reveal serious asymme...
Gavin Yamey, Patricia García, Fatima Hassan, Wenhui Mao et al.
During the covid-19 pandemic, we have seen the best of international collective action and its limits. Global scientific cooperation drove the development of safe, highly effective covid-19 vaccines in under one year. 1 Yet we have also witnessed global vaccine inequity, 2 in which low and middle in...
Tripti Pande, Madhukar Pai, Faiz Ahmad Khan, Claudia M. Denkinger
An estimated 9 million new tuberculosis (TB) cases and 1.5 million deaths were caused by Mycobacterium tuberculosis in 2013 [1], more than 80% of which occurred in the 22 highest TB burden countries (HBCs). Among the confirmed incident cases, 4.9 million were pulmonary TB (PTB), of which 58% were ba...
Madhukar Pai, Prashant Yadav, Ravi Anupindi
Whether it is mobile phone service or vacation travel, good businesses know that success depends on providing a complete and customer-centric solution. Should patients with tuberculosis not be offered a complete solution that is patient-centred? After all, millions are affected1WHOGlobal tuberculosi...
Morten Rühwald, Sergio Carmona, Madhukar Pai
The ongoing COVID-19 mass testing and vaccination campaigns are the result of unprecedented financial investments, rapid research and development, collaborative science, and innovation in delivery systems. It would be a shame to not leverage these systems for other priorities in global health. Befor...
Lekha Puri, Collins Oghor, Claudia M. Denkinger, Madhukar Pai
Xpert MTB/RIF (Cepheid, Sunnyvale, CA, USA) is the biggest recent advance in tuberculosis diagnosis, and since 2010 more than 15 million cartridges have been procured through concessional pricing ($9·98 per cartridge in 2015).1WHOWHO monitoring of Xpert MTB/RIF roll-out.http://www.who.int/tb/laborat...
Joel Shyam Klinton, Petra Heitkamp, Aamna Rashid, Bolanle Olusola Faleye et al.
The COVID-19 pandemic has impacted health systems and health programs across the world. For tuberculosis (TB), it is predicted to set back progress by at least twelve years. Public private mix (PPM)has made a vital contribution to reach End TB targets with a ten-fold rise in TB notifications from pr...
Vineet Bhatia, Suman Rijal, Mukta Sharma, Akramul Islam et al.
Over the decades, the global tuberculosis (TB) response has evolved from sanatoria-based treatment to DOTS (Directly Observed Therapy Shortcourse) strategy and the more recent End TB Strategy. The WHO South-East Asia Region, which accounted for 45% of new TB patients and 50% of deaths globally in 20...
Lena Faust, A. Zimmer, Mikashmi Kohli, Senjuti Saha et al.
Senjuti Saha, Madhukar Pai
Several low- and middle-income countries (LMICs) have responded to COVID-19 much better than expected—despite little help from high-income nations. LMICs can learn from the COVID-19 experience and re-imagine healthcare delivery. Using Bangladesh and India as examples, we explain how COVID-19 investm...
Yenew Kebede, Nqobile Ndlovu, Susan Nabadda, Charles Sawadogo et al.
Persistent gaps in access to quality diagnostic tests undermine progress toward improved health outcomes and resilience to disease outbreaks in Africa. Furthermore, resources for strengthening laboratory systems have faced growing constraints owing to recent reductions in official direct financial a...